secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2025-10-06T23:59:59+00:00
Accession:  0001628280-25-044212
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas presents positive Phase 1 data for ARV-102; biomarker modulation in CSF seen
--------------------------------------------------------------------------------

- ARV-102 well tolerated up to 200 mg single dose and 80 mg daily; no SAEs or discontinuations.
- Dose-dependent CSF exposure confirmed in healthy volunteers and Parkinson's patients.
- Daily doses ≥20 mg reduced PBMC LRRK2 by >90%; 200 mg dose in patients achieved 97% reduction.
- CSF proteomics showed decreases in lysosomal and neuroinflammatory microglial markers after 14 days.
- Arvinas plans to report multiple-dose Parkinson's data in 2026 and initiate Phase 1b PSP trial H1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/0001628280-25-044212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000162828025044212/arvn-20251005.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-044212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer